Phase II trial of HM781-36B in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of or unfit for platinum-containing therapy
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Poziotinib (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Mar 2019 Planned End Date changed from 1 Aug 2016 to 1 Jul 2019.
- 14 Mar 2019 Planned primary completion date changed from 1 Aug 2016 to 1 Jul 2019.
- 31 Aug 2018 Biomarkers information updated